Lots of great data and abstracts for myeloma this year at #ASH20; here, in no particular order, are my ‘top 10’ myeloma-related abstracts with a focus on clinical relevance #mmsm #ASH20BD [thread] @mtmdphd

1) #143 (Perrot): IFM-2009, Early vs Late ASCT in newly dx’d MM. ASCT leads to prolonged PFS but not OS. Why? PFS2 is longer in the delayed ASCT arm! ASCT still important at some point in disease. Need to take into account whether pt will be able to get ASCT at relapse! #ASH20BD

2) #141 (Gay): Survival analysis from FORTE. KRd+ASCT has > PFS than KRd alone and KCd+ASCT. Indicating that quality of induction and transplant are both important! Also, maintenance converts 32-46% of MRD-pos pts to MRD-neg. #mmsm #mmMRD #ASH20BD

3) #551 (Facon): TOURMALINE-MM2: IRd vs. Rd in transplant-ineligible newly dx’d MM. A negative study, and jiving with personal experience that Ixazomib is unfortunately not a great proteasome inhibitor. #mmsm #ASH20BD

4) #177 ( @DMadduri): CARTITUDE-1, Cilta-cel in R/R MM. Check out that sCR rate of 56%! CRS grade 3+ = 4% but ICANS grade 3+ 10%. The problem: CAR+ T cells not abundant at 6 months, will this affect duration of response? #mmsm #ASH20BD

5) #180 (Garfall): Teclistamab, BCMA x CD3 bispecific ab. ORR an impressive 64% (many VGPR or better). CRS 50%, ICANS 5%. Like all these studies, need longer follow-up. #mmsm #ASH20BD

6) #2318 (Paiva): MRD Kinetics in TOURMALINE-MM4. Shows that patients who converted from MRD+ to MRD-neg had similar PFS to patients with sustained MRD-negativity. What matters is getting to MRD-negativity! #mmsm #mmMRD #ASH20BD

7) #1554 (Gozzetti): DART4MM: Using daratumumab for MRD-positive disease. 28 pts with MRD-pos dz received dara for 6 mos. 9/17 (53%) achieved MRD-negativity but 6 have lost MRD-negativity. This type of study can be framework for MRD-guided trials. #mmsm #mmMRD #ASH20BD

8) #1397 ( @jagoda_jasielec ): Plug here for the MMRC trial investigating quadruplet Dara+KPd in R/R MM. nCR or better in 55% (including high risk patients!) and 55% MRD negativity by flow cytometry. Would be great option if received VRd/ASCT in frontline. #mmsm #ASH20BD

9) #290 (Chari): GPRC5D x CD3 bispecific T-cell engager (Talquetamab) with promising efficacy of 78% ORR, but will need more data as we hear about recommended phase 2 dosing. #mmsm #ASH20BD

10) #725 (Trudel): Belantamab mafodotin + Pom/Dex in R/R MM. Most had ASCT & were PI/Len refractory w/ ~50% dara refractory. ORR was 86% (VGPR or better in 66%) with main toxicity being keratopathy. As dara gets moved to frontline, may need options like this. #mmsm #ASH20BD